Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Under the Prescription Drug User Fee Act, the FDA has set a target action date of 17 August 2026.
Drug Development
Asahi Kasei acquires German company Aicuris
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
UCB to purchase Neurona and NRTX-1001 for $1.15bn
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Nucleai and Sirona Dx to provide new proteomics solution for pharma companies
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
